AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12145220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12145220 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg glibenclamide
Number of subjects: 24
Study 12145220 — intervention group
Group type: EXPERIMENTAL
Intervention: All three drugs
Number of subjects: 24
Study 12145220 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 24
Study 9521834 — intervention group
Group type: EXPERIMENTAL
Intervention: Liking judgments
Number of subjects: 0
Study 9521834 — intervention group
Group type: EXPERIMENTAL
Intervention: Disliking judgments
Number of subjects: 0
Study 9521834 — intervention group
Group type: EXPERIMENTAL
Intervention: Brighter and darker judgments
Number of subjects: 0
Study 9521834 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exposure to novel shapes
Number of subjects: 0
Study 7809806 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adhesiolysis
Number of subjects: 58
Study 3393916 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin, bleomycin, and methotrexate/leucovorin (PBM) before local regional treatment
Number of subjects: 224
Study 3393916 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy with cisplatin and infusion 5-fluorouracil
Number of subjects: 224
Study 3393916 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with PBM after surgery and/or radiotherapy
Number of subjects: 224
Study 30586750 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 25096
Study 30586750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25096
Study 28198196 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation module
Number of subjects: 8
Study 28198196 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional awareness module
Number of subjects: 8
Study 28198196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive flexibility module
Number of subjects: 8
Study 28198196 — intervention group
Group type: EXPERIMENTAL
Intervention: Countering emotional behaviors module
Number of subjects: 8
Study 27557300 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 6693
Study 27557300 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 6693
Study 24300595 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey supplementation
Number of subjects: 33
Study 24300595 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein supplementation
Number of subjects: 33
Study 24300595 — intervention group
Group type: COMPARATOR
Intervention: Control carbohydrate
Number of subjects: 33
Study 24300595 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training (CET)
Number of subjects: 33
Study 22982082 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple P Online (TPOL) intervention
Number of subjects: 116
Study 22982082 — intervention group
Group type: COMPARATOR
Intervention: Internet-use-as-usual control group
Number of subjects: 116
Study 19220672 — intervention group
Group type: EXPERIMENTAL
Intervention: Allowed to drink water for up to one hour prior to endoscopy (group B)
Number of subjects: 128
Study 19220672 — intervention group
Group type: COMPARATOR
Intervention: Nil by mouth for 6 h prior to endoscopy (group A)
Number of subjects: 128
Study 17325557 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (1.0 g/kg/d amino acids starting within the first day and 1.0 g/kg/d lipid added the next day)
Number of subjects: 72
Study 17325557 — intervention group
Group type: COMPARATOR
Intervention: Conventional nutrition (10% glucose and electrolytes in the first 72 hours, followed by 0.5 g/kg/d amino acids and lipid)
Number of subjects: 72
Study 17325557 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition
Number of subjects: 72
Study 17325557 — intervention group
Group type: COMPARATOR
Intervention: Conventional nutrition
Number of subjects: 72
Study 14741063 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg intravenously over 30 min)
Number of subjects: 18
Study 14741063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 14741063 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 18
Study 11480793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 600 mg/day
Number of subjects: 62
Study 11480793 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ascorbic acid)
Number of subjects: 62
Study 9747403 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance therapy
Number of subjects: 74
Study 9747403 — intervention group
Group type: COMPARATOR
Intervention: Non-specific counselling
Number of subjects: 74
Study 7826055 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-ml milkshake preload
Number of subjects: 133
Study 7826055 — intervention group
Group type: COMPARATOR
Intervention: No preload
Number of subjects: 133
Study 3046889 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand A levothyroxine sodium tablets
Number of subjects: 0
Study 3046889 — intervention group
Group type: COMPARATOR
Intervention: Brand B levothyroxine sodium tablets
Number of subjects: 0
Study 29663458 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine schedule A (0, 1, and 2 months)
Number of subjects: 46
Study 29663458 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine schedule B (0, 1, and 6 months)
Number of subjects: 46
Study 29663458 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine schedule C (0, 1, and 12 months)
Number of subjects: 46
Study 26898567 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA root-end filling
Number of subjects: 52
Study 26898567 — intervention group
Group type: COMPARATOR
Intervention: Gutta-percha filling smoothing
Number of subjects: 52
Study 24632495 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia (21% O2)
Number of subjects: 8
Study 24632495 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (12% O2)
Number of subjects: 8
Study 24632495 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia with restraint of respiratory chemoreflex
Number of subjects: 8
Study 23730838 — intervention group
Group type: EXPERIMENTAL
Intervention: 420 mg silymarin three times a day
Number of subjects: 32
Study 23730838 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg silymarin three times a day
Number of subjects: 32
Study 23730838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19942469 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 75mg on 2 consecutive days a month (2CDM)
Number of subjects: 0
Study 19942469 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5mg/d
Number of subjects: 0
Study 19942469 — intervention group
Group type: COMPARATOR
Intervention: Placebo (historical control)
Number of subjects: 0
Study 19942469 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 5mg (historical control)
Number of subjects: 0
Study 19095129 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 157
Study 19095129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 15888560 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ghrelin (3.6 nmol/kg)
Number of subjects: 9
Study 11868007 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 135
Study 11868007 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine plus fibrin glue
Number of subjects: 135
Study 10613617 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 microg 1,25-dihydroxyvitamin D3 administered at 8 AM
Number of subjects: 6
Study 10613617 — intervention group
Group type: COMPARATOR
Intervention: 2 microg 1,25-dihydroxyvitamin D3 administered at 8 PM
Number of subjects: 6
Study 10613617 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-dose measurements)
Number of subjects: 6
Study 10613617 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 microg 1,25-dihydroxyvitamin D3 at both times
Number of subjects: 6
Study 7604798 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg once daily
Number of subjects: 20
Study 7604798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once daily
Number of subjects: 20
Study 2235230 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (100 mg of phospholipid per kilogram of body weight)
Number of subjects: 100
Study 2235230 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant
Number of subjects: 100
Study 843188 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance under open conditions
Number of subjects: 127
Study 843188 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance under double blind conditions
Number of subjects: 127
Study 843188 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid withdrawal at a rate of 10% of initial dose per week
Number of subjects: 127
Study 843188 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual withdrawal at a rate of 3% of initial dose per week
Number of subjects: 127
Study 31721368 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exploration intervention (playing with and exploring blocks once a day for 8 weeks)
Number of subjects: 59
Study 31721368 — intervention group
Group type: COMPARATOR
Intervention: Book reading (control condition)
Number of subjects: 59
Study 31721368 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exploration intervention
Number of subjects: 59
Study 29654893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 732
Study 29654893 — intervention group
Group type: COMPARATOR
Intervention: Doripenem
Number of subjects: 732
Study 26505268 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐technique (slow aspiration)
Number of subjects: 482
Study 26505268 — intervention group
Group type: COMPARATOR
Intervention: R‐technique (rapid aspiration)
Number of subjects: 482
Study 25511081 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-Balance-Cognitive (SBC) training
Number of subjects: 182
Study 22590935 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose group receiving acetated Ringer's solution containing 1% glucose (n = 10)
Number of subjects: 20
Study 22590935 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving acetated Ringer's solution without glucose (n = 10)
Number of subjects: 20
Study 20083374 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser
Number of subjects: 10
Study 20083374 — intervention group
Group type: COMPARATOR
Intervention: PDL (pulsed-dye laser)
Number of subjects: 10
Study 18635183 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 10 days per month for 6 months
Number of subjects: 63
Study 18635183 — intervention group
Group type: COMPARATOR
Intervention: Ethinyl estradiol plus drospirenone
Number of subjects: 63
Study 15876901 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg daily
Number of subjects: 29
Study 15876901 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 45 mg daily
Number of subjects: 29
Study 15876901 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone taper
Number of subjects: 29
Study 15876901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 14551836 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position technique with one assistant
Number of subjects: 0
Study 14551836 — intervention group
Group type: COMPARATOR
Intervention: Supine position technique with two assistants
Number of subjects: 0
Study 10692600 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT at 10(‐3) M
Number of subjects: 24
Study 10692600 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT at 10(‐5) M
Number of subjects: 24
Study 10692600 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 24
Study 9058493 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (TTS 50, 50 micrograms/die)
Number of subjects: 22
Study 9058493 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE, 0.625 mg/die)
Number of subjects: 22
Study 8373213 — intervention group
Group type: EXPERIMENTAL
Intervention: FEM group (5‐FU, epirubicin (EPIR), and MMC)
Number of subjects: 15
Study 8373213 — intervention group
Group type: COMPARATOR
Intervention: FAM group (5‐FU, adriamycin (ADM), and mitomycin C)
Number of subjects: 15
Study 8373213 — intervention group
Group type: COMPARATOR
Intervention: FAM group
Number of subjects: 15
Study 8373213 — intervention group
Group type: EXPERIMENTAL
Intervention: FEM group
Number of subjects: 15
Study 3017401 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg once daily for 5 days
Number of subjects: 30
Study 3017401 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg once daily for 10 days
Number of subjects: 30
Study 29678994 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (supervised resistance and aerobic exercise performed three times per week for the first 6 months, transitioning to once a week for months 7-12, and self-managed from months 13-36)
Number of subjects: 168
Study 29678994 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 168
Study 29678994 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 168
Study 26626806 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent gait analysis insole with strict 20 kg partial weight bearing for 6 weeks
Number of subjects: 10
Study 26626806 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait analysis parameters (load, activity, gait time over 20 kg weight bearing, maximum ground reaction force)
Number of subjects: 10
Study 25454414 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) alternating with fixed-dose rate gemcitabine
Number of subjects: 98
Study 25454414 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose rate gemcitabine alone
Number of subjects: 98
Study 22283640 — intervention group
Group type: EXPERIMENTAL
Intervention: OmniPod system
Number of subjects: 29
Study 22283640 — intervention group
Group type: COMPARATOR
Intervention: Conventional CSII
Number of subjects: 29
Study 20299189 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 800 mg
Number of subjects: 395
Study 20299189 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1200 mg
Number of subjects: 395
Study 20299189 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 400 mg
Number of subjects: 395
Study 20299189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 18403189 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g eicosapentaenoic acid (EPA) plus 0.3 g docosahexaenoic acid (DHA) per day for 8 weeks
Number of subjects: 0
Study 18403189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15707563 — intervention group
Group type: EXPERIMENTAL
Intervention: Female condom (FC)
Number of subjects: 400
Study 15707563 — intervention group
Group type: EXPERIMENTAL
Intervention: Male condom (MC)
Number of subjects: 400
Study 15707563 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention
Number of subjects: 400
Study 11239530 — intervention group
Group type: COMPARATOR
Intervention: Diane 35 (2 mg of cyproterone acetate and 35 microg of ethinyl estradiol)
Number of subjects: 40
Study 11239530 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane 35 plus finasteride (5 mg daily)
Number of subjects: 40
Study 9895419 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS (galacto-oligosaccharides) 9 g daily
Number of subjects: 14
Study 9895419 — intervention group
Group type: COMPARATOR
Intervention: Control (2 control yoghurts daily)
Number of subjects: 14
Study 8049922 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on age, shock, myocardial disease, cerebrovascular disease, renal disease.
Number of subjects: 500
Study 8049922 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 500
Study 8049922 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupture
Number of subjects: 500
Study 8049922 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock
Number of subjects: 500
Study 8049922 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial disease
Number of subjects: 500
Study 8049922 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrovascular disease
Number of subjects: 500
Study 8049922 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal disease
Number of subjects: 500
Study 8049922 — intervention group
Group type: EXPERIMENTAL
Intervention: Size of the aneurysm
Number of subjects: 500
Study 3051991 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (sustained-release preparation, titrated from 240 to 360 mg/day in a twice-daily regimen)
Number of subjects: 96
Study 3051991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 8160593 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable defibrillator
Number of subjects: 230
Study 8160593 — intervention group
Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 230
Study 101315 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered sodium cromoglycate (400 mg to 600 mg, four times daily)
Number of subjects: 5
Study 30614138 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow induction (Group L)
Number of subjects: 50
Study 30614138 — intervention group
Group type: COMPARATOR
Intervention: Standard induction (Group S)
Number of subjects: 50
Study 30614138 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 27648821 — intervention group
Group type: EXPERIMENTAL
Intervention: FD‐Y0007
Number of subjects: 66
Study 27648821 — intervention group
Group type: COMPARATOR
Intervention: Coagrasper
Number of subjects: 66
Study 26362496 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Treatment Orders (CTOs)
Number of subjects: 336
Study 26362496 — intervention group
Group type: COMPARATOR
Intervention: Control (voluntary status via Section 17 leave)
Number of subjects: 336
Study 26362496 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO experience
Number of subjects: 336
Study 26362496 — intervention group
Group type: EXPERIMENTAL
Intervention: CTOs
Number of subjects: 336
Study 26362496 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 336
Study 23683683 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 49
Study 23683683 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic exercises
Number of subjects: 49
Study 23683683 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study 21817820 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (≤ 30 ml/kg) followed by crystalloid infusion
Number of subjects: 106
Study 21817820 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid only
Number of subjects: 106
Study 19531646 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical data from rats, sheep, and humans
Number of subjects: 156
Study 19531646 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer simulations of pulsatile LH profiles
Number of subjects: 156
Study 17954796 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) providing balanced, quantitative information
Number of subjects: 0
Study 17954796 — intervention group
Group type: COMPARATOR
Intervention: Standard information available from the screening program (Control)
Number of subjects: 0
Study 17954796 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 0
Study 15234290 — intervention group
Group type: EXPERIMENTAL
Intervention: Farnsworth-Munsell 100-hue test
Number of subjects: 2701
Study 15234290 — intervention group
Group type: COMPARATOR
Intervention: Deferred-treatment group
Number of subjects: 2701
Study 15234290 — intervention group
Group type: COMPARATOR
Intervention: Immediate-treatment group
Number of subjects: 2701
Study 11802511 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AG)
Number of subjects: 45
Study 9741505 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated t-PA regimen
Number of subjects: 1030
Study 9741505 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct related artery (RCA/Lcx vs. LAD)
Number of subjects: 1030
Study 9741505 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 1030
Study 9741505 — intervention group
Group type: EXPERIMENTAL
Intervention: History of smoking
Number of subjects: 1030
Study 9741505 — intervention group
Group type: COMPARATOR
Intervention: Time from symptom onset to treatment
Number of subjects: 1030
Study 8064454 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg
Number of subjects: 0
Study 8064454 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Number of subjects: 0
Study 8064454 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 650 mg
Number of subjects: 0
Study 8064454 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 650 mg plus codeine 60 mg
Number of subjects: 0
Study 8064454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2908306 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg
Number of subjects: 0
Study 2908306 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 0
Study 2908306 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg
Number of subjects: 0
Study 2908306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31974637 — intervention group
Group type: EXPERIMENTAL
Intervention: Becker Muscular Dystrophy (BMD) patients
Number of subjects: 20
Study 31056855 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat breakfast
Number of subjects: 0
Study 31056855 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat breakfast
Number of subjects: 0
Study 31056855 — intervention group
Group type: COMPARATOR
Intervention: Fasted condition (reference)
Number of subjects: 0
Study 30299482 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser vaporization (Group 2)
Number of subjects: 60
Study 30299482 — intervention group
Group type: COMPARATOR
Intervention: Cystectomy (Group 1)
Number of subjects: 60
Study 29738180 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel disposable ring (DR group)
Number of subjects: 470
Study 29738180 — intervention group
Group type: COMPARATOR
Intervention: Suture device (SD group)
Number of subjects: 470